Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

High definition mass spectrometer helps Swedish drug discovery programme

Waters : 08 November, 2007  (New Product)
Swedish based biotechnology firm Medivir has selected the Waters Synapt HDMS System to improve the company’s drug discovery efforts in the area of protease inhibitor research.
The results of the research will help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis, and high blood pressure.

Installed in June 2007, the Synapt High Definition Mass Spectrometry (MS) System is yielding significant information that is assisting with the decision-making process and helping Medivir reach its drug discovery milestones.

“Medivir is constantly reviewing opportunities to improve research output both in terms of quantity and quality. This investment in the Waters Synapt HDMS instrument has been seen as a very important vehicle to increase research output and to provide high quality support for the discovery disciplines,” said Medivir’s vice president of discovery research, Bertil Samuellson, PhD.

'The sensitivity of this instrument is significantly greater than the average quadrupole time-of-flight instrument and gives us more complete metabolic profiles,” says Kurt Benkestock, senior research scientist, analytical chemistry department, who supports many of Medivir’s research efforts. “At one time, we relied on outside resources to give us the information we needed. Now with the Synapt HDMS System, we can acquire the data we need in house and move candidates into advanced development phases faster.”

After carefully evaluating all its options, Medivir chose Waters Synapt HDMS System coupled to a Waters Acquity UltraPerformance LC (UPLC) System over all the conventional high-resolution, two-dimensional LC-MS technologies offered by other mass spectrometry suppliers.

“The reason we went with Waters Synapt System is that the instrument outperformed the others based on 22 performance criteria,” said Benkestock.

Other intangible aspects of the selection process were important as well. “Waters is good at listening to its customers, understanding their requirements, and adding features and making improvements that help us meet our scientific requirements,” added Benkestock.

Benkestock’s plans for the Synapt HDMS System are far-ranging including structure elucidation of metabolites and impurities, ligand screening during early drug discovery, protein and peptide work, protein identification and studying post-translation modifications, and target characterisation.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo